Perl, Alexander E <br/><br/>
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Mar 2012 
 - 1716-25 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-11-2346  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cytarabine--therapeutic use<br/>Drug Administration Schedule<br/>Etoposide--therapeutic use<br/>Female<br/>Humans<br/>Leukemia, Myeloid, Acute--metabolism<br/>Male<br/>Middle Aged<br/>Mitoxantrone--therapeutic use<br/>Phosphorylation<br/>Pilot Projects<br/>Ribosomal Protein S6--metabolism<br/>Signal Transduction--drug effects<br/>Sirolimus--therapeutic use<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors